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ABSTRACT
Background: The association of an increased
risk to develop melanoma in patients with
prostate cancer has recently been confirmed.
Purpose: The postulated etiologic relationship
between prostate cancer and the subsequent
occurrence of melanoma is discussed.
Methods: A man with previous prostate cancer
who developed melanoma on the plantar
surface of his left great toe is described and the
possibility of high levels of endogenous
androgens promoting not only prostate
cancer, but also increased risk of melanoma
are reviewed.
Results: Modification of the host immune
response, alteration of chromosome telomere
length, and/or imbalance of androgen level
(presenting as severe teenage acne) are
potential mechanisms whereby high levels of
endogenous androgens may contribute to the
association between prostate cancer and risk of
melanoma.
Conclusions: An increased surveillance for
melanoma should be considered in prostate
cancer patients. Complete skin examination in
men who have had prostate cancer—especially
in those individuals diagnosed with prostate
cancer prior to age 68 years—should regularly
be performed.
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INTRODUCTION
Melanoma is the fifth most commonly
diagnosed cancer among men in the United
States and may, in part, be etiologically
associated with androgen levels or androgen
receptors in the tumor or both [1–6]. Prostate
cancer is an androgen-related malignancy [7–11].
The statistically significant development of
malignant melanoma in prostate cancer patients
has recently been confirmed [12]. A man with
previous prostate cancer who developed
melanoma on the plantar surface of his left
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great toe is described and the postulated etiologic
relationship between prostate cancer and the
subsequent occurrence of melanoma is discussed.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
CASE REPORT
A 59-year-old Caucasian male presented with
asymptomatic black discoloration of his left big
toe. At least 5 years earlier, he had originally
noted some dark spots on the undersurface of
his toe. Recently, in November 2013, he was
prompted to seek medical attention since he
thought new fainter spots had appeared which
looked like a bruise, but were irregular in shape
and colored.
As a teenager, he had acne. He had been
treated with various topical preparations. In
addition, during high school, he received oral
tetracycline for at least 3 years.
His past medical history was also remarkable
for adenocarcinoma of the prostate, diagnosed
at age 51 years. He had mild lower urinary tract
symptoms in late 2004; in April 2005 he had an
abnormal digital rectal examination of his
prostate and his prostate-specific antigen was
elevated at 7.1 ng/ml. In May 2005, he
underwent a trans-rectal biopsy of his prostate
that showed a Gleason score of 4 ? 3 with
bilateral involvement.
Treatment was initiated with bicalutamide
(Casodex, Astrazeneca, Delaware, USA) 50 mg
daily. His prostate-specific antigen dropped to
0.3 ng/ml by July 2005. Seven months later, in
December 2005, leuprolide (Lupron Depot,
AbbVie Inc., Chicago, USA) injections, every
3 months, were added.
A magnetic resonance imaging (MRI) study
in January 2006 showed extension of the tumor
outside the prostate into the seminal vesicles
and surrounding tissues (stage T3b
radiographically). From March 2006 to May
2006, he was treated with external beam
radiation. He continued to receive androgen
deprivation therapy for approximately 2 years.
The last leuprolide injection was in December
2006 and he stopped using bicalutamide in
March 2007. His prostate-specific antigen
continues to remain below 0.4 ng/ml.
Examination of the plantar surface of his left
big toe showed three areas of black-brown
hyperpigmentation (Fig. 1). Each patch had
fading, irregular-shaped borders. The proximal
macule was 15 9 12 mm with a lighter proximal
area and a darker distal area; both areas were
biopsied and each showed melanoma in situ. In
addition, the distal dark macule (5 9 5 mm and
closer to the tip of the toe) and the lateral dark
macule (6 9 4 mm and near the second toe)
Fig. 1 Three patches of black-brown hyperpigmentation
with fading irregular-shaped borders are present on the
plantar surface of the left big toe. Biopsies from the
proximal lighter area and the distal darker area of the larger
patch closest to the foot both showed melanoma in situ.
All three of the pigmented patches, in addition to 5 mm of
normal-appearing adjacent skin, were excised
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were also biopsied; microscopic examination
showed melanocytic hyperplasia and atypical
intraepidermal melanocytic proliferation,
respectively. With regard to management,
treatment of the latter diagnosis is similar to
that of melanoma in situ.
Complete excision of all three black-brown
patches, including an additional 5 mm margin
of normal-appearing skin, was performed and
the wound was covered with a full-thickness
skin graft.
DISCUSSION
Carcinoma of the prostate is the most common
non-cutaneous cancer in the United States [2].
Earlier epidemiology studies have observed an
increase in melanoma in men with a history of
prostate cancer [13, 14]. Recently, Li et al.
prospectively examined this issue and
confirmed the association between a personal
history of prostate cancer and an increased risk
of subsequent melanoma in white men [12,
15, 16].
High levels of endogenous androgens have
been postulated to contribute to the association
between prostate cancer and risk of melanoma.
Possible androgen-associated mechanisms of
pathogenesis have been hypothesized. Some of
these include host immune response
modification, chromosome telomere length
alteration, and androgen level imbalance
[9–11].
A compromised immune response may affect
the individual’s risk of developing melanoma.
Indeed, the host’s immune response can be
suppressed by androgens, promoting
tumorigenesis of not only prostate cancer but
also melanoma. In contrast, immunotherapy is
a potential therapeutic intervention for prostate
cancer and a patient’s response to melanoma
vaccine and survival can both be improved after
their immune status has been enhanced
following a blocking or elimination of
androgen signaling [17–21].
Telomeres are the tiny bits of DNA that cap
the ends of chromosomes [22]. They prevent
chromosomes from unraveling and fusing with
each other. Telomeres shorten not only as
people age but also each time a cell divides;
eventually, the cell dies when the telomere
becomes too short [22, 23]. However, an
increased risk of melanoma has been
associated with long telomeres [24].
Telomerase is an anti-aging enzyme [22, 23].
It protects telomeres from wearing down and
rebuilds them. Androgen exposure in vitro has
been demonstrated to stimulate telomerase
activity resulting in elongation of telomeres
and extension of melanocyte life span [25].
Hence, by increasing telomere DNA replication
and subsequent telomere length, androgens
may influence the risk of melanoma
development [26, 27].
Androgen imbalance may be an integral
component in the tumorigenesis of not only
prostate cancer, but also the enhanced
susceptibility to develop melanoma. An early
clinical manifestation of androgen imbalance is
acne [28]. Patients with severe acne, defined by
use of tetracycline for four or more years, have
an increased risk of prostate cancer [28, 29]. Li
et al. [12] also observed a significant positive
association between severe teenage acne and
melanoma risk.
The patient in this report had moderate to
severe acne as a teenager which may represent
an early indication of androgen imbalance. He
received tetracycline for at least 3 years when he
was in high school. He developed prostate
cancer at the age of 51 years. Subsequently, he
developed melanoma in situ on the sun
protected plantar left big toe. Similar to this
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man, Li et al. [12] also observed a higher hazard
ratio of melanoma among patients with
prostate cancer whose median age at diagnosis
was less than or equal to 68 years.
CONCLUSION
The association of an increased risk of
developing melanoma in patients with
prostate cancer has recently been confirmed.
Prostate cancer is an androgen-related
malignancy and high levels of endogenous
androgens, possibly resulting in modification
of the host immune response, alteration of
chromosome telomere length, and/or
imbalance of androgen level (presenting as
severe teenage acne). This may contribute to
the association between prostate cancer and risk
of melanoma. It may be warranted to regularly
perform complete skin examination in men
who have had prostate cancer, especially in
those individuals diagnosed with prostate
cancer prior to age 68 years.
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